Quarterly Activities/Appendix 4C Cash Flow Report
Released
Released
Announcement PDF
ASX Announcement – 31 July 2025
QUARTERLY ACTIVITIES & CASHFLOW REPORT
Highlights
•
•
•
•
•
•
•
•
•
•
Receipts from customers of $2.7M with positive net cashflow from operations of $0.2M
Positive net cash inflow from operations of ~$1.3M for the full year
Second TrialsWest site opened in 2024 in Osborne Park, WA, achieved profitability
Completed the material clinical trial services agreement announced in Aug 2023, with the master
file provided to the international global-major-pharma customer
First ten patients dosed in the major-pharma $13.8M clinical trial services agreement, announced
in Nov 2024, with the clinical trial progressing to plan and on schedule
Several software-as-medical-device (SaMD) service contracts awarded or extended by globalpharma customers, with a total value of ~$4.5M across 2 to 4-year terms
Strong bid and tender activity with several major SaMD service proposals being considered by
pharmas, including two opportunities with new pharma customers
Third TrialsWest clinical trial site in Mandurah, WA, confirmed and secured - to commence clinical
trial service delivery in the next quarter
‘Bridge Project’ to connect Resonance’s SaMD image-analysis systems directly to customer PACS
platforms, vastly improving customer experience, commenced commercial testing
Cash at bank of $3.0M at quarter-end, and net cash of $0.1M (net of $2.9M debt)
Resonance Health Limited (Resonance Health or Company) (ASX: RHT) is pleased to release its Appendix 4C
and Quarterly Activities & Cashflow Report for the quarter ended 30th June 2025.
Operational Update
Resonance Health made significant progress in each of its 3-business focus areas; (i) Clinical Trial Management
CRO Services (Resonance Clinical), (ii) Software-as-a-Medical Device Image Analysis Services (SaMD), and (iii)
Clinical Trial Site Services (TrialsWest) (collectively, the Group).
Resonance Clinical
The two global-major-pharma clinical trial contracts being serviced by Resonance Clinical progressed with the
first trial successfully completed and the clinical trial master file being provided to the international sponsor
(see ASX release, 18 Aug 2023). The second material services agreement, worth $13.8M (see ASX release, 19
Nov 2024), achieved a key milestone during the quarter with the tenth patient being dosed. This trial remains
on track, with further revenue milestones expected in the coming periods. Resonance Clinical continues to bid
for new work, with a recent small trial win from a US biotech company, and a strong bid pipeline.
TrialsWest
The TrialsWest business continues to expand, underpinned by demand from existing and new clinical trial
pharmaceutical clients. The second TrialsWest site, opened in Osborne Park, WA, in 2024 (see ASX release, 8
Aug 2024), achieved profitability during the quarter. A third TrialsWest site, in Mandurah, WA, was identified
and secured post-period (see ASX release, 8 Jul 2025), with fit out of site now underway. These additional trial
sites are expected to support further revenue growth in FY26.
Resonance Health Ltd ABN: 96 006 762 492
141 Burswood Road, Burswood, WA 6100, AUSTRALIA
Postal: PO Box 108, Victoria Park, WA 6979, AUSTRALIA
www.resonancehealth.com
T + 61 8 9286 5300
info@resonancehealth.com
Software-as-a-Medical Device (SaMD)
The SaMD division secured ~$4.5M in new or extended service contracts with four global pharma companies,
including new customers. These contracts span multiple years and reflect the growing demand for Resonance
Health’s proprietary SaMD imaging analysis services. Several additional major bids are currently under
evaluation by existing and new customers.
The Company continues to expand its central-read analysis service offerings to cover more clinical trial imaging
endpoints. Consistent with this, the Company recently commenced a central-read service for Magnetic
Resonance Elastography (MRE) and visceral and subcutaneous fat volume quantification (VAT & SAT). The VAT
and SAT offerings will be provided to an international pharma customer in the coming months in connection
with their obesity related clinical trial.
Increased Automation & Improved Customer Workflow Integration
The Company commenced commercial testing of a new ‘bridge’ technology developed in-house to vastly
improve customer experience by allowing more direct integration of Resonance Health’s systems with
customers’ picture-archiving and communication-system (PACS) platforms. PACS is used globally in medical
fields including radiology practices and MRI centres and the new bridge technology will support more scalable
and seamless service delivery to customers.
Financial Summary
Net positive operating cash inflow for the quarter was $0.2M, with positive operating cashflow of ~$1.3M for
the full year reflecting careful cost control and strong operational performance.
Total customer receipts were $2.7M for the quarter, slightly lower than the prior quarter, but with a strong
finish to the year in June, pointing to robust momentum heading into FY26.
The Company closed the quarter with $3.0M in cash and net cash of $0.1M, after accounting for the NAB bank
financing facility ($2.9M outstanding).
With respect to item 6 of the Appendix 4C cash flow report for the quarter, payments to related parties
of approximately $137K were made during the quarter. This comprised of $42K paid to Mr Mitchell Wells
for consulting and company secretarial services provided during the quarter. The balance was
remuneration paid to non-executive directors for their services.
Page 2
Outlook
The Company enters FY26 with a strong foundation in place; major clinical trial contracts are underway or in
the bid process under evaluation, growing demand for SaMD services, and an expanding TrialsWest footprint.
The continued execution of the Company’s strategy across its three business segments - Resonance Clinical,
SaMD, and TrialsWest - positions the Company for sustained revenue growth and operational leverage.
To watch Mr Harrison’s video discussion about the expansion, please visit the Company’s InvestorHub:
https://investors.resonancehealth.com/link/y5aRly
Further Information
https://investors.resonancehealth.com
This announcement has been authorised for release in accordance with the delegated authority of the Board
of Directors of Resonance Health Ltd. For further information please contact:
Andrew Harrison – Chief Executive Officer
E: andrewh@resonancehealth.com
P: +61 (0)8 9286 5300
About Resonance Health
Resonance Health is an Australian healthcare technology and services company. The Company’s services are
used globally by clinicians in the management of human diseases and by pharmaceutical and therapeutic
companies in their clinical trials. Resonance Health has gained endorsement by leading physicians worldwide
for providing high quality quantitative assessments essential in managing diseases and drug development.
Resonance Health’s dedication to scientific rigour and quality has enabled it to achieve regulatory clearances
for a range of Software-as-Medical Devices (SaMDs) in the USA, Europe, UK, and Australia, and to proudly
carry ISO 13485 certification for the design and manufacture of medical devices. Regulatory cleared SaMD
products, some of which incorporate Artificial Intelligence (AI), include:
§ FerriScan®, a core-lab product that provides an accurate assessment of liver iron concentration (LIC)
through non-invasive MRI-based technology, for use in the assessment of individuals with iron overload
conditions. Internationally recognised as the gold standard in LIC assessment.
§ FerriSmart®, an AI-trained, non-invasive MRI-based device for the automated real-time assessment of LIC
in participants, calibrated against the global gold standard, FerriScan®.
§ HepaFatScan®, an MRI-based solution which provides a reliable non-invasive assessment of liver-fat in
liver tissue for use in the assessment of individuals with confirmed or suspected fatty-liver-disease.
§ HepaFatSmart ®, an AI-trained, non-invasive device for the automated real-time multi-metric assessment
of liver-fat, for the assessment of individuals with confirmed or suspected fatty liver disease.
§ LiverSmart®, an AI-trained, non-invasive MRI-based multi-parametric device combining FerriSmart® and
HepaFat-AI® into a consolidated report providing accurate assessment of LIC and liver fat.
§ CardiacT2*, the most widely accepted MRI method for assessing heart iron loading. Resonance Health
offers a dual analysis of FerriScan® and CardiacT2*.
The Company has a development pipeline of additional medical imaging analysis products and services,
including the MRI Liver Fibrosis Project, aimed at accurately assessing the presence and progression of liver
fibrosis utilising non-invasive MRI analysis
Page 3
The Company also has a clinical trials business which both manages clinical trials in Australia and includes the
site management operations of TrialsWest.
Stakeholders, including clinicians, participants, and shareholders, are encouraged to register their interest at
www.resonancehealth.com and to follow Resonance Health on LinkedIn.
Page 4
Rule 4.7B
Appendix 4C
Quarterly cash flow report for entities
subject to Listing Rule 4.7B
Name of entity
Resonance Health Limited
ABN
Quarter ended (“current quarter”)
96 006 762 492
30 June 2025
Consolidated statement of cash flows
Current quarter
$A’000
Year to date (12
months)
$A’000
2,722
13,965
(90)
(968)
(67)
(871)
(e) staff costs
(1,304)
(5,509)
(f)
(1,061)
(5,430)
5
44
(56)
(241)
-
212
20
46
169
1,248
-
(3,915)
(178)
(442)
(49)
(180)
1.
Cash flows from operating activities
1.1
Receipts from customers
1.2
Payments for
(a) research and development
(b) product manufacturing and operating
costs
(c) advertising and marketing
(d) leased assets
administration and corporate costs
1.3
Dividends received (see note 3)
1.4
Interest received
1.5
Interest and other costs of finance paid
1.6
Income taxes paid
1.7
Government grants and tax incentives
1.8
Other (provide details if material)
1.9
Net cash from / (used in) operating
activities
2.
Cash flows from investing activities
2.1
Payments to acquire or for:
(a) entities
(b) businesses
(c) property, plant and equipment
(d) investments
(e) intellectual property
(f)
other non-current assets
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 1
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Consolidated statement of cash flows
Current quarter
$A’000
Year to date (12
months)
$A’000
21
21
(206)
(4,516)
(80)
(320)
- Lease payments
(51)
(285)
- Net payments for cash backed
guarantees
(31)
(43)
3.10
Net cash from / (used in) financing
activities
(162)
(648)
4.
Net increase / (decrease) in cash and
cash equivalents for the period
4.1
Cash and cash equivalents at beginning of
period
3,196
6,854
169
1,248
2.2
Proceeds from disposal of:
(a) entities
(b) businesses
(c) property, plant and equipment
(d) investments
(e) intellectual property
(f)
other non-current assets
2.3
Cash flows from loans to other entities
2.4
Dividends received (see note 3)
2.5
Other (provide details if material)
2.6
Net cash from / (used in) investing
activities
3.
Cash flows from financing activities
3.1
Proceeds from issues of equity securities
(excluding convertible debt securities)
3.2
Proceeds from issue of convertible debt
securities
3.3
Proceeds from exercise of options
3.4
Transaction costs related to issues of
equity securities or convertible debt
securities
3.5
Proceeds from borrowings
3.6
Repayment of borrowings
3.7
Transaction costs related to loans and
borrowings
3.8
Dividends paid
3.9
Other:
4.2
Net cash from / (used in) operating
activities (item 1.9 above)
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 2
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Consolidated statement of cash flows
Current quarter
$A’000
Year to date (12
months)
$A’000
4.3
Net cash from / (used in) investing activities
(item 2.6 above)
(204)
(4,516)
4.4
Net cash from / (used in) financing activities
(item 3.10 above)
(162)
(650)
4.5
Effect of movement in exchange rates on
cash held
(22)
39
4.6
Cash and cash equivalents at end of
period
2,977
2,977
5.
Reconciliation of cash and cash
equivalents
Current quarter
$A’000
Previous quarter
$A’000
at the end of the quarter (as shown in the
consolidated statement of cash flows) to the
related items in the accounts
5.1
Bank balances
5.2
Call deposits
5.3
Bank overdrafts
5.4
Other (provide details)
5.5
Cash and cash equivalents at end of
quarter (should equal item 4.6 above)
6.
Payments to related parties of the entity and their
associates
6.1
Aggregate amount of payments to related parties and their
associates included in item 1
6.2
Aggregate amount of payments to related parties and their
associates included in item 2
2,977
3,180
-
16
2,977
3,196
Current quarter
$A'000
137
Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an
explanation for, such payments.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 3
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
7.
Financing facilities
Note: the term “facility’ includes all forms of financing
arrangements available to the entity.
Add notes as necessary for an understanding of the
sources of finance available to the entity.
Total facility
amount at quarter
end
$A’000
Amount drawn at
quarter end
$A’000
2,853
2,853
2,853
2,853
7.1
Loan facilities
7.2
Credit standby arrangements
7.3
Other (please specify)
7.4
Total financing facilities
7.5
Unused financing facilities available at quarter end
7.6
Include in the box below a description of each facility above, including the lender, interest
rate, maturity date and whether it is secured or unsecured. If any additional financing
facilities have been entered into or are proposed to be entered into after quarter end,
include a note providing details of those facilities as well.
NIL
Secured Financing Facility from National Australia Bank, facility expiry date is 31 March
2027. Interest rate is BBSY + 2.5% per annum.
8.
Estimated cash available for future operating activities
$A’000
8.1
Net cash from / (used in) operating activities (item 1.9)
169
8.2
Cash and cash equivalents at quarter end (item 4.6)
2,977
8.3
Unused finance facilities available at quarter end (item 7.5)
8.4
Total available funding (item 8.2 + item 8.3)
8.5
Estimated quarters of funding available (item 8.4 divided by
item 8.1)
2,977
N/A
Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as “N/A”. Otherwise, a
figure for the estimated quarters of funding available must be included in item 8.5.
8.6
If item 8.5 is less than 2 quarters, please provide answers to the following questions:
8.6.1
Does the entity expect that it will continue to have the current level of net operating
cash flows for the time being and, if not, why not?
Answer: N/A
8.6.2
Has the entity taken any steps, or does it propose to take any steps, to raise further
cash to fund its operations and, if so, what are those steps and how likely does it
believe that they will be successful?
Answer: N/A
8.6.3
Does the entity expect to be able to continue its operations and to meet its business
objectives and, if so, on what basis?
Answer: N/A
Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 4
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Compliance statement
1
This statement has been prepared in accordance with accounting standards and policies
which comply with Listing Rule 19.11A.
2
This statement gives a true and fair view of the matters disclosed.
Date:
31 July 2025
Authorised by: By the Board of Directors of Resonance Health Limited
Notes
1.
This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the
entity’s activities for the past quarter, how they have been financed and the effect this has had on its cash position. An
entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is
encouraged to do so.
2.
If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions
in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been
prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the
corresponding equivalent standard applies to this report.
3.
Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities,
depending on the accounting policy of the entity.
4.
If this report has been authorised for release to the market by your board of directors, you can insert here: “By the board”.
If it has been authorised for release to the market by a committee of your board of directors, you can insert here: “By the
[name of board committee – eg Audit and Risk Committee]”. If it has been authorised for release to the market by a
disclosure committee, you can insert here: “By the Disclosure Committee”.
5.
If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as
complying with recommendation 4.2 of the ASX Corporate Governance Council’s Corporate Governance Principles and
Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial
records of the entity have been properly maintained, that this report complies with the appropriate accounting standards
and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a
sound system of risk management and internal control which is operating effectively.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 5
Share your feedback
Discover